A & M Scientific East Africa Limited has announced the introduction of MaximBio’s HIV-1 Limiting Antigen (LAg) Avidity assay kits into the East African market, strengthening regional capacity for HIV surveillance, incidence estimation, and research-driven public health decision-making.
The newly introduced portfolio includes the HIV-1 LAg Avidity EIA Serum/Plasma Kit and the HIV-1 Limiting Antigen (LAg) Avidity DBS EIA Kit, both widely recognized tools used in distinguishing recent from long-term HIV-1 infections. These assays are essential components of HIV incidence studies, surveillance programs, and population-level monitoring initiatives implemented by public health institutions, research laboratories, and reference centers.
Supporting HIV Incidence and Surveillance Programs
The MaximBio HIV-1 LAg Avidity EIA assays are designed for use with either serum/plasma samples or dried blood spot (DBS) specimens, offering flexibility for both laboratory-based testing and field-based surveillance activities. The DBS format, in particular, supports sample collection in resource-limited and remote settings, enabling broader geographic coverage and improved data capture for national and regional HIV programs.
By enabling reliable classification of recent HIV-1 infections, the LAg Avidity assays play a critical role in estimating HIV incidence, evaluating the impact of prevention strategies, and guiding policy formulation.
Partnership with MaximBio
MaximBio, a U.S.-based diagnostic manufacturer, is internationally recognized for its expertise in immunoassay development and production. Its HIV-1 LAg Avidity assays are extensively used in surveillance studies and research initiatives worldwide and are valued for their consistency, robustness, and suitability for large-scale epidemiological applications.
Through this collaboration, A & M Scientific East Africa Limited aims to ensure local availability, technical support, and reliable supply of these specialized assays to laboratories and institutions across East Africa.
Advancing Public Health Research Capacity
The introduction of the MaximBio HIV-1 LAg Avidity EIA Serum/Plasma Kit and DBS EIA Kit aligns with A & M Scientific East Africa’s ongoing commitment to strengthening laboratory diagnostics and public health research infrastructure in the region.
By expanding access to advanced HIV surveillance tools, the company seeks to support governments, research organizations, and implementing partners in generating high-quality data critical to controlling and ultimately ending the HIV epidemic.